FIELD: medicine.
SUBSTANCE: invention represents a pharmaceutical formulation possessing an ability to inhibit cardiac arrhythmias, containing the type A botulinum toxin and mucopolysaccharide specified in a group containing chitosan, heparin, nadroparin, hyaluronic acid taken in a ratio of 1:(103-109), preferentially 1:(106-108) by weight respectively with the ingredients of the formulation taken in certain relations.
EFFECT: higher pharmacological activity, reduced required single dose for achieving the required therapeutic effect, prolonging the action of botulinum toxin and reduced side effects botulinum toxin.
8 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CHRONIC NEUROGENIC INFLAMMATION BY MODIFIED CLOSTRIDIAL TOXIN | 2010 |
|
RU2568844C2 |
| METHOD FOR TREATING VENTRICULAR ARRHYTHMIAS (VARIANTS) | 2016 |
|
RU2651044C2 |
| Liquid composition containing botulinum toxin and a stabilizing agent, and a method for its preparation | 2017 |
|
RU2748653C2 |
| METHODS OF TREATING INCONTINENCE ASSOCIATED WITH SEXUAL ACTIVITY | 2012 |
|
RU2578475C2 |
| STABILIZED NON-PROTEIN COMPOSITIONS OF CLOSTRIDIAL TOXIN | 2017 |
|
RU2762607C2 |
| METHOD FOR BOTULINUM TOXIN PRODUCTION | 2014 |
|
RU2627159C2 |
| CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE | 2009 |
|
RU2524429C2 |
| LIQUID COMPOSITION STABILIZING BOTULINUM TOXIN | 2019 |
|
RU2812790C2 |
| METHOD OF DETERMINING THE ACTIVITY OF BOTULINUM TOXIN USING CELLS | 2019 |
|
RU2803123C2 |
| BIOPREPARATIONS COMPOSITIONS FOR INTRAVESICAL INSTILLATION | 2015 |
|
RU2720991C2 |
